Distribution of Pulmonary Neuroendocrine Cells and Neuroendocrine Bodies among Healthy and Asthmatic Adult Lung Subjects by Minnick, Caroline
Minnick 
 
   
    
1 
 
 
 
 
 
 
Distribution of Pulmonary Neuroendocrine Cells and Neuroendocrine 
Bodies among Healthy and Asthmatic Adult Lung Subjects 
 
 
By: 
Caroline Minnick 
 
 
Senior Honors Thesis 
Biology 
University of North Carolina at Chapel Hill 
 
 
19 March 2019 
 
 
 
 
 
 
Approved: 
_______________________ 
Thesis Advisor 
_______________________ 
Reader 
_______________________ 
Reader 
Minnick 
 
   
    
2 
 
TABLE OF CONTENTS 
1.	 ABSTRACT ............................................................................................................................................. 3	
2.	 INTRODUCTION ................................................................................................................................... 5	
3.	 METHODS .............................................................................................................................................. 8	
3.1.	 Lung Sample Donor Demographics ........................................................................................................ 8	
3.2.	 Tissue Preparation for Immunohistochemistry ........................................................................................ 8	
3.3.	 Immunolabeling of Gastrin Releasing Peptide ........................................................................................ 9	
3.4.	 Slide and Data Analysis ......................................................................................................................... 11	
3.5.	 Quantitative PCR of GRP ...................................................................................................................... 11	
4.	 RESULTS .............................................................................................................................................. 13	
4.1.	 Normal/Healthy Adult Subjects ............................................................................................................. 14	
4.2.	 Asthmatic Adult Subjects ...................................................................................................................... 17	
5.	 DISCUSSION AND CONCLUSIONS ................................................................................................. 22	
6.	 ACKNOWLEDGEMENTS ................................................................................................................... 24	
7.	 REFERENCES ...................................................................................................................................... 25	
 
LIST OF TABLES 
Table 1:	 Demographics of Subjects and Experimental Use ................................................................................... 8	
 
LIST OF FIGURES 
Figure 1: Representative Microscope Images of PNECs and NEBs in the Trachea and Distal Airways of 
Normal Subject ...................................................................................................................................... 14	
Figure 2:	 Density and Distribution of PNECs and NEBs in the Lungs of Normal Healthy Adult 
Subjects. ................................................................................................................................................. 15	
Figure 3:	 NEB Density in the Distal Airway of Normal Healthy Subjects ........................................................... 16	
Figure 4:	 mRNA Expression of GRP in Normal Subjects .................................................................................... 17	
Figure 5:	 Density and Distribution of PNECs and NEBs in the Lungs of Asthmatic Subjects. ........................... 18	
Figure 6:	 NEBs in the Distal Airway of Asthmatic Subjects ................................................................................ 19	
Figure 7:	 Density of NEBs in Terminal Bronchioles Normal and Asthmatic Subjects. ....................................... 20	
Figure 8:	 Density of PNECs in Trachea and Middle Airway Sections in Normal and Asthmatic 
Subjects .................................................................................................................................................. 21	
 
 
Minnick 
 
   
    
3 
1. ABSTRACT 
The airways of the lungs contain an important collection of pulmonary neuroendocrine cells 
(PNECs). The role of these critical cells in development and in disease states is still being 
elucidated. The pulmonary neuroendocrine system’s known general function is cell signaling, as 
the cells are innervated and release a combination of peptides and amines. Gastrin-releasing 
peptide (GRP) is the most well-known peptide used for signaling in the human pulmonary 
neuroendocrine system, and it can be used as a biological marker of neuroendocrine cells via 
antibody. The cell organization is unique as the cells are present either as individual cells or as 
neuroendocrine bodies (NEBs) made of two or more cells. It has been previously suggested that 
asthmatic subjects have greater densities of PNECs and NEBs. Our objective of this project was 
to discern the impact of an asthma disease state on the overall organization of the pulmonary 
neuroendocrine system in terms of cell distribution on the proximal-distal axis and density. 
Following immunohistochemistry (IHC) staining for GRP, we measured cell density in the form 
of PNECs and NEBs for both normal and asthmatic subject samples. In normal subjects, the 
solitary pulmonary neuroendocrine cells presented with a notably higher density in the trachea 
than in more distal airways, whereas neuroendocrine bodies had the greatest density in distal 
airways, especially in terminal bronchioles. The results from IHC on normal subjects were 
confirmed by quantitative PCR (qPCR) performed on additional normal lung samples. The qPCR 
data revealed an increasing amount of GRP mRNA in the proximal-distal axis of the lungs. In 
asthmatic subjects, these same trends along the proximal-distal axis were present but less strong. 
In addition, there was a drastic decrease in NEBs in terminal airways compared to healthy 
subjects. Given that the two types of cell organization seen within the pulmonary neuroendocrine 
system are found in their highest densities in distinct lung sections, it is possible that unique roles 
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are maintained by these cells depending on their structure or location. In addition, the significant 
decrease in NEB density in distal airways of asthmatic subjects in comparison to healthy subjects 
may open doors for therapies and increased understanding of disease pathology. 
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2. INTRODUCTION 
Pulmonary neuroendocrine cells (PNECs) are a specialized cell type found in the epithelium of 
the lungs. They were first noted in scientific literature in the 1940s when Feyrter and Fröhlich 
discovered clear cells, which were soon thereafter named as neuroendocrine cells1. As research is 
still developing and solidifying in regards to the pulmonary neuroendocrine system, there have 
been many names and proposed roles for these cells throughout the years. During the 1990s, a 
fairly concrete consensus was reached among researchers, and the two major, yet distinct, 
functions of the pulmonary endocrine system were clarified2. The first role of the proposed dual 
role is, during early lung development, PNECs may function to monitor and modulate the growth 
and differentiation of the lung via their ability to secrete peptides, amines, and neurotransmitters. 
Due to this supposed role of the system, it is commonly found that the densities of PNECs and 
NEBs are higher in fetuses and very young, developing humans3. The second half of the dual 
role is, later in fetal life and postnatally, the cells may act as a system of chemoreceptors2. There 
is data that suggests that PNECs sense inhaled inputs (allergen, toxins, etc.) or states such as 
hypoxia and coordinate lung outputs to respond to the stimuli8,3. While the embryonal lung and 
neonatal lung have been large areas of investigation for researchers, the adult lung is a very 
active area for discovery and growth with respect to the understanding of the physiology and 
function of the pulmonary neuroendocrine system in both normal subjects and diseased subjects. 
Pulmonary neuroendocrine cells can exist independently of one another as solitary cells or in 
clusters as neuroendocrine bodies. These cell types are primarily localized at airway branch 
points throughout the lung where they can transmit signals to other nearby cells8.  
Neuroendocrine cells are distinctive in that they are long, extending from lumen to basement 
membrane with fingerlike projections that extend in many directions away from the main cell 
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body. The irregular cell shape is accompanied by secretory granules that contain amines and 
peptides for secretion and signaling, with the capability of eliciting an immune response8. There 
is a multitude of secretions that a neuroendocrine (NE) cell is capable of releasing. The most 
common human secretion is gastrin-releasing peptide (GRP), often called bombesin-like 
peptide3. GRP is thought to be responsible in part for the production of some cytokines which 
work to recruit immune cells8. In addition, PNECs appear to work through another of their 
products, GABA, to stimulate epithelial mucus production. Adding to their distinction, NEBs are 
typically more heavily innervated than PNECs, and it is presumed that solitary PNECs and NEBs 
occupy different roles within the lung epithelium3. 
Much research is currently being conducted to determine if PNECs may be useful for therapies 
for various lung conditions and diseases including chronic obstructive pulmonary disease 
(COPD), cystic fibrosis (CF), and asthma. Prior research has indicated that there are notably 
more PNECs in lung samples of asthmatics6. Pengfei Sui, et al. conducted a research project to 
determine the role of PNECs during an allergen challenges in asthmatics. They determined that 
the secretions of the pulmonary neuroendocrine system affected goblet cell hyperplasia and 
interleukin 5 (IL5) production8, both of which have notable roles within an allergen response 
(mucus production and immune response)8. These results coupled with the increased density of 
PNECs suggest causality for the increase in allergen responses in subjects with asthma8. Knock-
out mice for this cell system showed decreased allergen response efficiency and effectiveness8. 
While the density of PNECs relative to other cell types within the lung is minimal, they seem to 
play an important and essential role in amplifying and perpetuating the allergen response signal8. 
While the pulmonary neuroendocrine system has been relevant in scientific research for over 60 
years, there are still many questions regarding the true role the cells play in the lung environment 
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as a whole throughout development and into adulthood. Understanding the way these cells 
distribute themselves throughout the lung based on their two known structures could provide a 
basis for research into physiology and purpose. A distinct or opposing distribution pattern of 
PNECs and NEBs in healthy or diseased subjects could uncover nuances of the pulmonary 
neuroendocrine system that the community is still unfamiliar with. In an attempt to map the 
relative distributions of PNECs and neuroendocrine bodies (NEBs) in lungs of healthy adult 
subjects, I performed immunohistochemistry in various lung regions of twelve subjects (six 
healthy and six asthmatic). The immunohistochemistry results were confirmed through qPCR 
analysis of nine healthy subjects. In this study, we were able to examine the relationship between 
cell type and location in order to advance the understanding of the roles of pulmonary 
neuroendocrine bodies and solitary neuroendocrine cells. In addition, through the comparison of 
samples from healthy subjects and asthmatic subjects, this project allowed us to explore potential 
differences in the proliferation pattern of the pulmonary neuroendocrine system in diseased 
systems. 
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3. METHODS 
3.1. Lung Sample Donor Demographics 
Lung tissue was taken from 16 donors. The demographics of the donors are provided in Table 1, 
along with information related to the types of experiments in which they were used. 
Table 1: Demographics of Subjects and Experimental Use 
Subject Sex Age Disease Smoking History IHC qPCR 
H10260 M 43 Normal Never smoker X  
H10287 F 22 Normal Never smoker X  
H10321 F 19 Normal Never smoker X  
H10437 M 37 Normal Never smoker X  
H10170 F 17 Normal Never smoker X  
H10253 F 55 Normal Never smoker X  
H10701 M 24 Normal Never smoker  X 
H10700 F 59 Normal Never smoker  X 
H10651 M 55 Normal 0PY (1 cigarette/6 mo.)  X 
H10671 F 35 Normal Marijuana daily for 12 yr.  X 
H10687 F 53 Normal 2PY (quit 30 yr. ago)  X 
H10709 M 28 Normal 7PY (quit 1 yr. ago)  X 
H10708 M 25 Normal Never smoker  X 
H10724 M 15 Normal Never smoker  X 
96671 M 27 Normal Never smoker  X 
H10312 F 16 Asthma Never smoker X  
H10722 M 21 Asthma Never smoker X  
H10417 F 10 Asthma Never smoker X  
H10313 M 58 Asthma Smoker X  
H10320 F 34 Asthma Smoker X  
H10433 F 26 Asthma Smoker X  
3.2. Tissue Preparation for Immunohistochemistry 
Lung tissue samples from 16 human subjects were used for immunohistochemistry.  All lung 
tissue samples were acquired from the University of North Carolina Tissue and Cell Culture 
Procurement Core. Human lung tissue was procured under the UNC Office of Research Ethics 
Biomedical Institutional Review Board-approved protocol No. 03-1396. Tissues were fixed in 
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10% neutral buffered formalin for 24-36 hours, embedded in paraffin, cut into 5µm thick 
sections, and placed on slides. Prior to beginning the steps of immunohistochemistry, the slides 
were baked in an oven at ~48ºC oven for 6-12 hours. The tissue samples were then 
deparaffinized through a series of changes in enough xylene and ethanol to cover the sections. 
The first step of deparaffinization was three changes in xylene for ten minutes each. This was 
followed by two changes in 100% ethanol for five minutes each, then one change in 95% and 
70% ethanol both for five minutes each. To rehydrate the slides, they soaked in phosphate 
buffered saline (PBS) pH 7.2 for five minutes in glass Coplin jars. To block endogenous 
peroxidase activity, the slides were placed in Coplin jars containing a solution of 60mL methanol 
and 1mL hydrogen peroxide for 15 minutes. The slides were transferred to a Coplin jar 
containing PBS for and gently shaken for five minutes. 
3.3. Immunolabeling of Gastrin Releasing Peptide 
A solution of 4% donkey serum was prepared by combining a ratio of 1mL normal donkey 
serum (Jackson Immunoresearch Labs Inc.) to 24 mL of phosphate buffered saline with Tween 
(PBST). The solution was transferred to plastic Coplin jars (large enough for five slides) and the 
slides soaked for two hours at room temperature. After the slides blocked with donkey serum, the 
slides were placed in a slide tray with a very small pool of water to maintain humidity (not 
touching the slides).  
The primary antibody used in this study was the mouse monoclonal antibody GRP E-11: sc-
271045 kappa light chain (Santa Cruz Biotechnology Inc.). The primary antibody was combined 
with 4% donkey serum (reused from step before) at a ratio of 1:100.  For primary antibody 
incubation, 500 µL of the solution was applied to all experimental slides, and they were 
subsequently covered with plastic cover slips. For negative (isotype) control slides, mouse IgG 
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antibody (Santa Cruz Biotechnology Inc.) was used in place of the primary anti-GRP antibody. 
The incubating slides were kept at 4ºC overnight. The next day, the slides were rinsed with 
PBST three times for ten minutes each. The secondary antibody used in this study was 
biotinylated donkey anti-mouse IgG (Jackson ImmunoResearch Labs Inc.). The secondary 
antibody was prepared at a 1:200 dilution with 4% donkey serum in PBST. The same application 
technique used for the primary antibody (500 µL per slide with plastic cover slip) was applied to 
the secondary antibody. 
The incubating slides were kept at room temperature for one hour. After the hour, the slides were 
rinsed in glass Coplin jars with PBST three times for ten minutes each. During these rinses, the 
Vector ABC (avidin/biotin complex) reagent was prepared using the Vectastain Elite ABC-
Horseradish Peroxidase kit (Vector Laboratories). This solution was prepared by combining 10 
mL of PBST, two drops of A (avidin), and two drops of B (biotinylated HRP). The ABC reagent 
was allowed to incubate on the shaker for 30 minutes. After the slides finished rinsing in PBST, 
the ABC reagent was applied using the same technique that was used for both the primary and 
the secondary antibody. The slides incubated for 30 minutes. After the 30 minutes, the slides 
were once again rinsed three times with PBST for ten minutes each. During these rinses, the 
diaminobenzidine (DAB) reagent was prepared according to the following steps. In a separate 
beaker, 200 mL of acetate buffer, 1.6 g of sodium chloride, and 2.0 g nickel sulfate were 
combined and stirred until completely dissolved. After complete dissolution, 0.095 g of 3’3 
diaminobenzidine was added to the solution, and the solution was stirred for ten minutes. The 
completed DAB reagent was then filtered into a plastic staining dish. To the filtered DAB 
solution, 25 µL of hydrogen peroxide was added.  
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Once the slides were finished incubating with Vector ABC, the slides were then stained in the 
following manner. To begin, the slides were soaked in 0.1M acetate buffer for one minute. Then 
the slides were transferred to the DAB solution (with hydrogen peroxide) for five minutes. The 
slides then soaked in 0.1M Tris saline for one minute and then Tris cobalt for four minutes. 
Afterwards, the slides were washed in DI water briefly and then transferred to fast red to soak for 
four minutes. Finally, the slides were washed with multiple rounds of DI water to remove excess 
fast red. To dehydrate and clear the slides, they were dipped 20 times in 70% ethanol, 95% 
ethanol, 100% ethanol and two changes of xylene. With the experimental steps complete, the 
slides were finished and covered using glass cover slips and mounting buffer. 
3.4. Slide and Data Analysis 
The prepared slides were scanned and digitized using an Olympus VS120 light microscope with 
a 40X objective lens. Using ImageJ software, the basement membranes of all airways on each 
slide were measured. The number of PNECs and NEBs for each region of measured basement 
membrane was counted and recorded. These numbers were then converted to number of 
cells/bodies per millimeter of basement membrane in order to determine a density. The average 
density was calculated for each airway section (trachea, middle, and distal) for each subject. The 
collection of airways that makes up the middle classification are primary and secondary bronchi. 
Distal airways are tertiary bronchi and bronchioles. 
3.5. Quantitative PCR of GRP 
We also performed quantitative PCR using samples from nine normal subjects as denoted in 
Table 1. The relative amounts of GRP mRNA found in the various airway regions were 
determined via qPCR in an effort to confirm findings from the prior IHC analysis. The qPCR 
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protocol used in this project was based on the protocol performed by Kenichi Okuda, et al7. All 
qPCR was performed using the Applied Biosystems 7500 Real Time PCR Systems. 
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4. RESULTS 
In order to identify and quantify the cells of interest in the lung samples, we performed IHC 
specific for GRP, the human marker protein for the pulmonary neuroendocrine system. Once 
stained and identifiable, the cells were counted and normalized to the length of the basement 
membrane in order to determine densities. In this quantification, PNECs and NEBs were 
considered distinct entities and their numbers were kept separate. Densities were then compared 
from different lung regions in order to develop a sense of distribution throughout the lung in both 
healthy and asthmatic subjects. Following immunohistochemistry, quantitative PCR was done to 
validate and verify the findings for normal subjects. 
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Figure 1: Representative Microscope Images of PNECs and NEBs in the Trachea and 
Distal Airways of Normal Subject 
 
Microscope images showing isotope control sections and sections using the anti-GRP antibody after IHC. The 
presence of neuroendocrine cells (of any form) is only seen in experimental sections, as seen from the dark, specific 
staining. 
 
4.1. Normal/Healthy Adult Subjects 
Initially, we performed IHC specific for GRP on the samples from normal subjects. We 
measured the density of both solitary neuroendocrine cells and neuroendocrine bodies from three 
distinct lung sections (trachea, middle airway, and distal airway) in order to decipher any 
significant distribution patterns. On average, for each subject 2-4 middle and distal airways were 
studied. In normal lung samples, we found a statistically significant increase in PNECs in the 
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trachea versus the distal airways (Welch’s t-test, p≤0.05) and a statistically significant increase in 
NEBs in distal airways versus in the trachea (Welch’s t-test, p≤0.01) (Figure 2). 
Figure 2: Density and Distribution of PNECs and NEBs in the Lungs of Normal 
Healthy Adult Subjects. 
 
Column Graph Displaying the Densities of PNECs (Left Panel) and NEBs (Right Panel) From Various Subjects, 
Organized by Lung Section. There is a significant difference between trachea and distal airways with both cell 
types (Welch’s t-test, p≤0.05 - left, p≤0.01 - right). 
Based on the high density of pulmonary neuroendocrine bodies found in distal airways (shown in 
Figure 2 right panel), we decided to conduct specific distribution studies in only the distal 
airways. There is evidence to suggests that other cell types in the airway epithelium have 
significant differences in genes and in the proteins they involve with when comparing non-
terminal and terminal bronchioles9. As a next step, we separated the distal airway classification 
into terminal bronchioles and non-terminal bronchioles to quantify the difference in distribution 
within these sub-classifications (Figure 3). We found a statistically significant increase in the 
number of NEBs in terminal bronchioles versus non-terminal bronchioles (Welch’s t-test, 
p≤0.05). 
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Figure 3: NEB Density in the Distal Airway of Normal Healthy Subjects 
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Column graph comparing NEB density in normal subjects, organized by sub-classification of the distal airway. 
There is a significant difference between the two sub-classes (Welch’s t-test, p≤0.01). 
To enhance the results we obtained from IHC, we performed qPCR on freshly excised airway 
tissue sections from 9 normal adult subjects listed in Table 1. We used qPCR to determine the 
relative amounts of GRP mRNA located in the various lung regions (Figure 4). Although there 
was a trend towards more GRP mRNA in the distal airways, this was not statistically significant 
(Welch’s t-test, p=0.1306). 
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Figure 4: mRNA Expression of GRP in Normal Subjects 
Tra
ch
ea
Mi
dd
le
Di
sta
l
-5
0
5
10
15
20
Normal GRP qPCR
R
el
at
iv
e 
m
R
N
A 
ex
pr
es
si
on
ns
ns
 
Column graph demonstrating relative amounts of GRP mRNA expression from 9 normal subjects, organized by lung 
section. There are no significant findings in regards to trachea/middle airways versus distal (Welch’s t-test, 
p=0.1306). 
4.2. Asthmatic Adult Subjects 
To expand the scope of our study, we conducted IHC on tissue samples from 6 asthmatic 
subjects. We calculated the density of both solitary PNECs and NEBs in the trachea, middle, and 
distal sections from the six asthmatic subjects (Figure 5). Unlike the normal subjects, the IHC 
results from the asthmatic subjects did not show significant region-specificity in PNECs and 
NEBs densities, although there was an average increase in cell density in the trachea for solitary 
PNECs and in the distal airways for NEBs, which was a similar trend seen in the normal subjects 
(Welch’s t-test, p=0.0596 and p=0.1095). 
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Figure 5: Density and Distribution of PNECs and NEBs in the Lungs of Asthmatic 
Subjects. 
 
Column graph depicting densities of PNECs and NEBs in asthmatic lung tissue, organized by lung section. No 
significant difference in cell density was found between any of the sections (Welch’s t-test, p=0.0596 and 
p=0.1095). 
As with the normal subjects, we did more specific IHC analysis of the NEB densities within 
distal airways. Separating the distal classification into non-terminal and terminal bronchioles 
allowed us to break down the distribution of NEBs further for comparison (Figure 6). There was 
a significant difference in distribution of NEBs between non-terminal and terminal bronchioles, 
with a noted increased in terminal bronchioles (Welch’s t-test, p≤0.01). 
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Figure 6: NEBs in the Distal Airway of Asthmatic Subjects 
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Column graph demonstrating the respective densities of NEBs in asthmatic lung samples, organized by sub-class of 
the distal airway. There is a significant increase in NEB density as airways move from non-terminal to terminal 
(Welch’s t-test, p≤0.01). 
Given that an objective of this study was to elucidate potential differences in lung physiology 
between diseased and normal subjects, we chose to compare the relative densities (from IHC) of 
NEBs in terminal airways. Both normal and asthmatic subjects produced lung samples with a 
statistically significant increase in NEB densities along the proximal-distal axis of the lung 
airways, so we chose to explore this trend for significant differences (Figure 7). There was a 
significant difference in NEB densities of the terminal airways between asthmatic and normal 
samples, with a noted decrease in the asthmatic subjects (Welch’s t-test p≤0.05). 
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Figure 7: Density of NEBs in Terminal Bronchioles Normal and Asthmatic Subjects. 
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Column graph showing the densities of NEBs in terminal bronchioles, organized by subject demographic (Normal 
versus Asthmatic). The average decrease in NEB density in asthmatic subjects in comparison to normal 
physiology is statistically significant (Welch’s t-test, p≤0.05). 
To go along with the data in Figure 7, we chose to compare density of PNECs between normal 
and asthmatic subjects in both the trachea and in the middle airways using the data from IHC 
(Figure 8). In both regions (trachea and middle airways), the sections from the asthmatic subjects 
had lower PNEC densities than the normal subjects. The difference is not statistically significant, 
though the trend may still be of value (Welch’s t-test, p=0.4832 and p=0.1637) 
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Figure 8: Density of PNECs in Trachea and Middle Airway Sections in Normal and 
Asthmatic Subjects 
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Column graph showing the densities of PNECs in normal and asthmatic subjects, organized by section (trachea or 
middle airway).  The average decrease in PNEC density in trachea and middle airway sections from asthmatic 
subjects compared to normal subjects is clear, but not statistically significant (Welch’s t-test, p=0.4832 and 
p=0.1637). 
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5. DISCUSSION AND CONCLUSIONS 
Throughout the course of this project, we were able to discern a few key details regarding the 
organization and distribution of the cells within the pulmonary neuroendocrine system that have 
yet to be stated in existing literature. The first of these was that in tissue samples from normal 
subjects, the density of PNECs in proximal airways is greater than in more distal airways. The 
trend is reversed for NEBs in normal subjects, with their highest densities in distal airways, 
especially terminal bronchioles. For asthmatic subjects, the findings are similar, but less 
convincing given the weaker statistics. Potentially the most interesting finding is the significant 
decrease in the density of NEBs found in terminal bronchioles in asthmatic subjects when 
compared to healthy subjects. Taking all of these findings together, there are some apparent 
differences in distribution depending on cell structure and on subject pathology. 
The opposing distribution pattern of PNECs and NEBs suggests distinct roles for the two cell 
forms. The regions in which these two cell forms are primarily located are distinct and have 
different roles in the respiratory system. While PNECs are located in the largest conducting 
airway of the respiratory system, NEBs are located most heavily in the smallest airways that are 
more involved with chemo-sensing and detoxification5. Terminal bronchioles represent the 
junction of the conduction zone and respiration zone of the lung, and there may be a correlation 
between this unique location and the nuanced roll of NEBs. Previous research has provided 
much evidence to support the claim that NEBs are key players in chemo-sensing and oxygen-
sensing in the lungs, and the findings from our project coincide with the previous literature 
regarding this topic8. 
The distinct decrease in NEB density in terminal airways of asthmatic subjects in comparison to 
healthy subjects should be explored for its potential for therapeutic implication. These findings 
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are corroborated by the decrease in PNEC density in asthmatic subjects in both the trachea and 
the middle airways. Although the findings were not statistically significant, the data shows an 
overall decrease in neuroendocrine cells (of any form) in subjects with asthma. The presence of a 
difference between normal and asthmatic pathology yields many possibilities for exploration in 
regards to disease prevention, treatment, and therapy.  
Given the nature of the study, which utilized human lung samples, there was little room for 
standardization beyond assessing smoking history and general lung health. The tissue samples 
used in the study were taken from lungs rejected for transplant due to having been on the 
ventilator for an extended period of time. Human subjects leave room for a vast quantity of 
confounding factors and inconsistencies in data, which cell culture can mostly eliminate. There is 
some chance that variability among the subjects yielded unexpected and unknown data 
discrepancies. In addition, the sample sizes are each relatively small (<10), and conclusions 
drawn from the data could become stronger and more supported with an increase in sample size. 
In order to confirm the findings from asthmatic subjects, qPCR should be done in the same 
fashion that it was done for the normal subjects. Finally, a large aspect of this study revolves 
around the comparison of different disease states, and extrapolating the study to include 
additional diseases (including chronic obstructive pulmonary disease or cystic fibrosis) would 
continue to progress the goal of the study. 
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